Evommune (EVMN) Payables (2024 - 2026)

Evommune (EVMN) has 3 years of Payables data on file, last reported at $4.0 million in Q1 2026.

• Payables for Q1 2026 came in at $4.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (changed N/A YoY), and the FY2025 annual result was $7.8 million, down 6.15% from the prior year.
• Payables slipped to $4.0 million in Q1 2026 per EVMN's latest filing, from $7.8 million in the prior quarter.
• Over five years, Payables peaked at $8.3 million in Q4 2024 and troughed at $3.6 million in Q3 2025.
• A 3-year average of $5.9 million and a median of $5.9 million in 2025 frame the typical range for Payables.
• On a YoY basis, Payables climbed as much as 6.15% in 2025 and fell as far as 6.15% in 2025.
• A 3-year view of Payables shows it stood at $8.3 million in 2024, then retreated by 6.15% to $7.8 million in 2025, then slumped by 47.85% to $4.0 million in 2026.
• Business Quant data shows EVMN's Payables at $4.0 million in Q1 2026, $7.8 million in Q4 2025, and $3.6 million in Q3 2025.